Table 1 Changes in blood/fecal biomarkers associated with allergic/eosinophilic inflammation during dupilumab treatment
Duration from the recurrence of duodenal ulcer (months) | 0 | 3 | 6 | 9 | 12 | 15 | 18 | 20 |
|---|---|---|---|---|---|---|---|---|
| Â | PSL Start | Â | Â | DUP Start | Â | PSL Off | Â | Egg tolerance |
Eosinophil counts (/µl)(NR: 70—450) | 1747 | 747 | 365 | 598 | 126 | 366 | 412 | 461 |
Total IgE (U/ml) (NR: < 170) | 768 | ND | ND | 2324 | 1176 | 582 | 411 | 368 |
TARC (pg/ml) (NR: < 742) | 1030 | ND | ND | 620 | 237 | 175 | 129 | 241 |
IL-5 (pg/ml) (NR: < 4.0) | 9.4 | 5.4 | 4.5 | 4.2 | 0.9 | 1.4 | 1.3 | 0.8 |
IL-13 (pg/ml) (NR: < 13.2) | 22.4 | 24.4 | 24.3 | 60.4 | 13.7 | 16.4 | 21.7 | 15.1 |
Eotaxin-3 (pg/ml) (NR: < 16.7) | 37.7 | 29.6 | 21.4 | 26.6 | 13.1 | 16.9 | 16.3 | 15.0 |
Fecal Calprotectin (mg/kg) (NR: < 50) | 347 | 99 | 381 | 28 | 92 | 180 | ND | ND |